Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00408850
Status:
UNKNOWN
Last Update Posted:
2013-01-17
First Post:
2006-12-06
Brief Title:
Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity
Sponsor:
Baker Heart Research Institute
Organization:
Baker Heart Research Institute
Study Overview
Official Title:
Mechanisms of Sympathetic Overactivity in the Metabolic Syndrome Effects of Reversing Insulin Resistance by Drug Treatment
Status:
UNKNOWN
Status Verified Date:
2013-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An abdominal distribution of fat is associated with the greatest heart disease risk because commonly several risk factors of metabolic origin cluster in these individuals When this occurs the condition is called the metabolic syndrome
Increased activity of the sympathetic nervous system resulting in enhanced release of the stress hormone noradrenaline may be one mechanism by which adverse cardiovascular and metabolic sequela of the metabolic syndrome might be mediated Impaired insulin action may be one factor contributing to increased noradrenaline release
The aim of this Study is to determine whether treatment with a drug called pioglitazone which is known to improve insulin action results in reduced sympathetic nervous system activity and stress hormone release when compared to treatment with a dummy drug placebo
Increased activity of the sympathetic nervous system resulting in enhanced release of the stress hormone noradrenaline may be one mechanism by which adverse cardiovascular and metabolic sequela of the metabolic syndrome might be mediated Impaired insulin action may be one factor contributing to increased noradrenaline release
The aim of this Study is to determine whether treatment with a drug called pioglitazone which is known to improve insulin action results in reduced sympathetic nervous system activity and stress hormone release when compared to treatment with a dummy drug placebo
Detailed Description:
The rapidly growing burden of obesity together with a population that is becoming older raises the importance of effective strategies for the primary prevention and treatment of the metabolic syndrome in order to combat the epidemic of type 2 diabetes and to reduce the increased risk of cardiovascular mortality
Increased sympathetic nervous system activity may participate in the pathogenesis and complications of the metabolic syndrome This Study will use a randomised controlled design to evaluate the effects of pioglitazone treatment on sympathetic activity in middle-aged subjects with the metabolic syndromeThe results will generate new information on the neuroadrenergic effects of thiazolidinediones in this clinical setting This is relevant to the understanding of the pathophysiology of the metabolic syndrome and to its clinical management
Increased sympathetic nervous system activity may participate in the pathogenesis and complications of the metabolic syndrome This Study will use a randomised controlled design to evaluate the effects of pioglitazone treatment on sympathetic activity in middle-aged subjects with the metabolic syndromeThe results will generate new information on the neuroadrenergic effects of thiazolidinediones in this clinical setting This is relevant to the understanding of the pathophysiology of the metabolic syndrome and to its clinical management
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None